Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PHVS | 144 | neutral | 2/10 | Form 144: Director Elisabeth Bjork intends to sell 10,000 PHVS shares (~$293K) via a cashless stock option exercise. The | May 20, 2026 |
| CNEY | 3 | neutral | 2/10 | Yi Ming filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing no securities owned as of M | May 20, 2026 |
| MEHA | 8-K | mixed | 5/10 | Functional Brands Inc. reported the resignation of Tariq Rahim from the Board and his transition from CFO to Vice Presid | May 20, 2026 |
| LIMNW | 8-K | mixed | 6/10 | Liminatus Pharma entered a merger agreement to acquire InnocsAI LLC, a private CAR-T therapy company, for 1.6 billion sh | May 20, 2026 |
| AAVXF | 6-K | neutral | 2/10 | Abivax S.A. reported the results of its May 11, 2026 annual general meeting, where all 33 resolutions proposed by the Bo | May 20, 2026 |
| SUPN | 8-K | neutral | 3/10 | Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a $0.50-per-CVR cash | May 20, 2026 |
| HUMA | CLUSTER | neutral | 3/10 | Two C-suite insiders (CFO and Chief Medical Officer) sold ~$82K in open-market sales on 2026-05-18, while a director bou | May 20, 2026 |
| LXEO | CLUSTER | neutral | 2/10 | Two LXEO insiders, CEO and COO, sold a combined $24K in open-market sales on the same day, 9 days after Q1 2026 earnings | May 20, 2026 |
| BTAI | 144 | neutral | 2/10 | Richard I. Steinhart, an officer of BioXcel Therapeutics, filed a Form 144 to sell 6,845 shares of common stock valued a | May 20, 2026 |
| ZTS | 8-K | neutral | 2/10 | Zoetis declared a Q3 2026 dividend of $0.53 per share, payable September 1, 2026 to holders of record as of July 20, 202 | May 20, 2026 |
| SDGR | 8-K | neutral | 4/10 | Schrodinger's Chief Commercial Officer, Global Head of Software Sales and Marketing, Mannix Aklian, departed effective i | May 20, 2026 |
| REPL | CLUSTER | neutral | 4/10 | Three REPL insiders (CEO, CFO, and a director) sold a total of $319K in open-market sales on May 18, 2026, all at $5.08 | May 20, 2026 |
| ANVS | 424B5 | bearish | 6/10 | Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, pri | May 20, 2026 |
| ALKS | 8-K | neutral | 3/10 | Alkermes filed an 8-K reporting results of its 2026 annual meeting, where shareholders approved an amendment to the 2018 | May 20, 2026 |
| ACET | 10-K/A | neutral | 2/10 | Adicet Bio filed an amended 10-K/A to correct an inadvertent omission in Item 9A, the original filing lacked a statement | May 20, 2026 |
| VVOS | PRESS-RELEASE | mixed | 5/10 | Vivos Therapeutics reported Q1 2026 revenue of $5.14M (+70% YoY, 19.6% above consensus) but EPS of -$0.52 missed estimat | May 20, 2026 |
| RIGL | 8-K | neutral | 2/10 | Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approv | May 20, 2026 |
| OGEN | DEFA14A | neutral | 6/10 | Oragenics Inc filed a DEFA14A (definitive additional proxy soliciting materials) on May 20, 2026. The filing is related | May 20, 2026 |
| LGVN | PRESS-RELEASE | neutral | 4/10 | Longeveron issued a CEO letter detailing a strategic repositioning toward a capital-light, partnership-focused model, wi | May 20, 2026 |
| ELDN | PRESS-RELEASE | neutral | 3/10 | Eledon Pharmaceuticals will present new clinical data from its tegoprubart Phase 2 BESTOW trial and extension study at t | May 20, 2026 |
| EQ | PRESS-RELEASE | neutral | 3/10 | Equillium announced a virtual investor event on May 27, 2026, to present new preclinical data on AhR modulators and the | May 20, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | CEO Robert Blum and EVP Fady Malik sold a total of $849K in open-market transactions within a week of a $700M equity off | May 20, 2026 |
| AIM | PRESS-RELEASE | bearish | 7/10 | AIM ImmunoTech announced a heavily dilutive registered direct offering of 7,519,351 shares at $0.325/share, raising ~$2. | May 20, 2026 |
| MTEX | CLUSTER | bullish | 6/10 | Two directors purchased a total of $51K in open-market shares, representing 0.64% of the $8M market cap. This follows a | May 20, 2026 |
| JNJ | COURT-RULING | neutral | 1/10 | The Ninth Circuit affirmed the district court's dismissal of a product liability case against Janssen (JNJ subsidiary) a | May 20, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy with Anktiva (N-803) | May 20, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK filed a 6-K reporting a routine director shareholding notification: Non-Executive Director Dr. Hal Barron acquired 7 | May 20, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK plc filed a Form 6-K disclosing an immaterial acquisition of 74 ADS by non-executive director Dr. Hal Barron at $49. | May 20, 2026 |
| GILD | ANALYST-UPGRADE | bullish | 2/10 | Maxim Group double-upgraded GILD from Hold to Buy with a $165 price target, implying 26.4% upside from $130.50. The call | May 20, 2026 |
| LNAI | 8-K | bearish | 6/10 | Lunai Bioworks announced a 1-for-8 reverse stock split effective May 22, 2026, aimed at regaining compliance with Nasdaq | May 20, 2026 |